ABthera ADVANCE™
Open Abdomen Dressing
The next generation in temporary abdominal closure

Value Analysis Tool
ABTHERA ADVANCE™ Dressing

We are excited to introduce the next generation of temporary abdominal closure to the market: ABTHERA ADVANCE™ Open Abdomen Dressing. This new dressing includes a redesigned dressing configuration for drawing wound edges together, directly based upon the technology and success of ABTHERA™ Open Abdomen Negative Pressure Therapy.

The ABTHERA™ Open Abdomen Negative Pressure Therapy System is authorized under ABTHERA™ Therapy FDA clearance K120499 (see below). The ABTHERA ADVANCE™ Dressing has been directly added to the Medical Device Listing database (see final page), and can be referenced by visiting the links shown.

---

Dear Ms. Marsh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/centersOffices/CDRH/CDRHoffices/legm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson
Director
Division of Surgical, Orthopedic and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

View the ABTHERA™ Therapy FDA device listing online at abtheraadvance.com/FDA
View the ABTHERA™ Therapy FDA device listing online at abtheraadvance.com/FDA

Specifications

**ABTHERA™ Fenestrated Visceral Protective Layer**
- Dimensions: 665mm x 802mm
- Encapsulated Foam Thickness: 10mm
- Polyurethane Layer Thickness: 160 microns
- Shelf Life: 3 years at room temperature
- Sterile, Latex Free

Ordering Information

<table>
<thead>
<tr>
<th>Description</th>
<th>Item Number</th>
<th>Qty.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABTHERA ADVANCE™ Open Abdomen Dressing</td>
<td>ABT1055</td>
<td>5 per case</td>
</tr>
<tr>
<td>(Includes ABTHERA™ Fenestrated Visceral Protective Layer, ABTHERA ADVANCE™ Perforated Foam, Drape, and SENSAT.R.A.C.™ Tubing)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For use with negative pressure therapy provided by the V.A.C.ULTA™ Therapy Unit.

For more information call 800.275.4524, or visit abtheraadvance.com

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2020 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. LIT #29-A-366 • PRA-PM-US-00710 (08/20)